Secondary analysis of the RTS,S/AS01E phase 3 trial in 1292 African children aged 5–17 months: C-terminus IgG waned more slowly than NANP-repeat IgG and was independently associated with lower malaria risk (HR 0.60); maintained, not peak, IgG predicted protection.
Secondary analysisn = 1,292
Lara-Escandell et al. Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS,S/AS01E vaccination: an observational ancillary immunological study of a phase 3 clinical trial